Core Insights - The medical beauty industry in China is projected to grow, with a consumption penetration rate increasing from 3.2% in 2020 to 5.8% by 2025, indicating over 80 million people have undergone medical beauty procedures [1] - The brand "可复美" (Kefumei) under 巨子生物 (Giant Bio) is facing significant negative publicity due to allegations of product fraud related to its key ingredient, recombinant collagen [2][3] - The controversy has led to a substantial decline in Giant Bio's stock price, dropping nearly 30% from its peak of 87.1 HKD [3][25] Industry Overview - The medical beauty market is expanding rapidly, with a notable increase in consumer engagement and product usage [1] - The competitive landscape is intensifying, particularly with rival companies like 华熙生物 (Huaxi Bio) actively targeting Giant Bio amid the ongoing controversies [4][5] Company Performance - Giant Bio's revenue grew from 20 billion RMB in 2022 to 35.24 billion RMB in 2023, marking a 49.05% increase, and further to 55.39 billion RMB in 2024, with a 57.2% year-on-year growth [25] - Despite strong revenue growth, the company has faced challenges in maintaining investor confidence due to recent scandals, leading to a market capitalization drop of over 60 billion HKD [3][25] Product Controversies - The allegations against Kefumei include claims that the amount of recombinant collagen in its products is significantly lower than advertised, raising questions about product integrity [3][6] - Previous controversies involved undisclosed ingredients like epidermal growth factor (EGF), which is banned in cosmetic products, further complicating the brand's reputation [10][12][17] Market Dynamics - The ongoing disputes have prompted consumers to reconsider their loyalty to Kefumei, with potential shifts towards alternative brands like 修丽可 (Xiu Li Ke) and 敷尔佳 (Fu Er Jia) [27] - The company's reliance on sales and marketing over research and development is evident, with a stark contrast between sales expenses and R&D investment, which may impact long-term sustainability [28][29]

Core Viewpoint - The article discusses the rise and subsequent challenges faced by Juzi Biotechnology, highlighting its rapid growth in the beauty industry and the controversies surrounding its flagship product, the collagen stick, amid accusations of ingredient falsification [4][11][12]. Company Overview - Juzi Biotechnology, founded by Yan Jianya and Fan Daidi, has become a significant player in the beauty industry, particularly known for its "recombinant collagen" technology [10][11]. - The company achieved a market value of over 450 billion yuan in May, making its founders the richest in Shaanxi province [4]. - Juzi Biotechnology's net profit increased from 1 billion yuan in 2022 to 2.06 billion yuan in 2024, with a peak gross margin of 82% [11][21]. Recent Controversies - In May, Juzi Biotechnology faced backlash from Huaxi Biotechnology, which accused it of misleading marketing regarding the safety and efficacy of its products [6][19]. - Influencer "Big Mouth Doctor" Hao Yu claimed that the collagen stick contained only 0.0177% of the advertised recombinant collagen, significantly below the stated minimum of 0.1% [13][17]. - Juzi Biotechnology's response included a denial of the allegations and a commitment to legal action against misinformation campaigns [7][15]. Market Impact - Following the allegations, Juzi Biotechnology's stock price dropped over 8%, reducing its market capitalization from 909 billion HKD to 735 billion HKD within ten days [7][11]. - The controversy has affected not only Juzi Biotechnology but also other companies in the recombinant collagen sector, leading to a decline in their stock prices [7][11]. Competitive Landscape - The article highlights the competitive tension between Juzi Biotechnology and Huaxi Biotechnology, with both companies investing heavily in marketing and facing scrutiny over their product claims [21]. - Juzi Biotechnology's marketing expenses exceeded 2 billion yuan in 2024, while Huaxi Biotechnology's marketing costs were reported at 2.464 billion yuan [21].

Core Viewpoint - The ongoing controversy regarding the authenticity of collagen content in the "可复美胶原棒" product has sparked significant industry attention, with both 华熙生物 and 巨子生物 responding to the allegations made by 郝宇 and the testing institution involved [1][2]. Group 1: Company Responses - 华熙生物 issued a statement supporting 郝宇, indicating that they have conducted thorough evaluations and testing of the claims made against their products, and are willing to cooperate with regulatory bodies regarding the testing results [1]. - 巨子生物's 可复美 brand acknowledged the apology from the testing institution used by 郝宇 but stated their intention to pursue legal action against those spreading false information [2][3]. Group 2: Industry Implications - The dispute highlights the growing scrutiny within the medical aesthetics industry regarding product integrity and consumer trust, as both companies emphasize their commitment to transparency and consumer rights [2].

Core Viewpoint - The controversy surrounding the collagen content in the "可复美重组胶原蛋白肌御修护次抛精华" product has raised significant concerns regarding the accuracy of its labeling and the validity of the testing methods used to assess its ingredients [2][5]. Group 1: Product Testing and Claims - A beauty influencer claimed that the collagen content in the product was only 0.0177%, which is below the national standard minimum of 0.1% for non-trace ingredients [2]. - The influencer's testing method, HPLC, is not recognized by current industry standards, leading to questions about the reliability of the results [5]. - 可复美's internal tests reportedly show collagen content between 0.27% and 0.28%, which complies with the labeling regulations [5]. Group 2: Regulatory Compliance and Labeling - According to the "Cosmetic Labeling Management Measures," non-trace ingredients must be listed separately if they are present in amounts greater than or equal to 0.1% [5]. - 可复美 asserts that "soluble collagen" is listed seventh in the ingredient order, which aligns with regulatory requirements [5]. - The influencer's claim that the actual collagen content is 0.0177% raises concerns about potential false labeling practices [5]. Group 3: Market Impact - The product, known as "胶原棒," is a top-selling item for 可复美, with over 1 million units sold through a single link on its flagship store [5]. - The timing of the controversy, just before the "618" shopping festival, could lead to increased returns and cautious behavior from distributors [5].

Core Viewpoint - The recent controversy surrounding Giant Biological (巨子生物) has led to a significant decline in its stock price and raised questions about the integrity of its flagship product, "Recombinant Collagen" [1][2][6] Company Overview - Giant Biological, established in September 2001, is a leader in the global recombinant collagen market, with a registered capital of 68,752.179 million RMB [3] - The company's product line includes "Recombinant Collagen Essence," which claims to enhance skin firmness and elasticity [3] Controversy Details - A report by Dr. Hao Yu accused Giant Biological of product fraud, stating that the collagen content in its "Recombinant Collagen Essence" was only 0.0177%, below the non-trace standard of 0.1% [3][4] - The company has strongly denied these allegations, asserting that all products undergo rigorous quality control and testing [4][5] Market Impact - Following the controversy, Giant Biological's stock price fell by over 8% on May 26, 2023, closing at 73.600 HKD, resulting in a market capitalization of 788 billion HKD [1][6] - The company's market value has decreased from 900 billion HKD to 788 billion HKD due to the ongoing scandal [7] Financial Performance - For 2024, Giant Biological is projected to have a revenue of 5.678 billion RMB, with a year-on-year growth of 56.53% [8] - The company's net profit is expected to be 2.062 billion RMB, reflecting a growth of 42.06% [8] - Despite strong revenue growth, the company's R&D expenditure is only 107 million RMB, accounting for less than 2% of its revenue [8]

Core Viewpoint - The article discusses allegations against Juzi Biotechnology regarding the authenticity of its recombinant collagen products, leading to a significant drop in its stock price and market value [1][2][4][8]. Group 1: Allegations and Responses - Beauty influencer "Big Mouth Doctor" accused Juzi Biotechnology of serious fraud, claiming that its recombinant collagen serum could not be detected as advertised, with a reported collagen content of only 0.0177% [1][8][9]. - Juzi Biotechnology's brand, Kefu Mei, firmly denied these allegations, stating that their product tests showed collagen content exceeding 0.1%, and they have engaged third-party testing agencies for further verification [4][12]. Group 2: Financial Impact - Following the allegations, Juzi Biotechnology's stock opened down over 8% and closed with a decline of 4.04%, resulting in a market capitalization below 800 billion HKD [2]. - The company has experienced rapid revenue growth, with a reported revenue increase from 9 billion to 55 billion CNY from 2019 to 2024, and a net profit rise from 5.5 billion to 20.6 billion CNY during the same period [15][16]. Group 3: Company Background and Market Position - Juzi Biotechnology, led by Fan Daidi, a vice president of Northwest University, is a leader in the recombinant collagen sector, with a product range that includes functional skincare, medical dressings, and medical devices [14][16]. - The company has established a strong market presence, with its products available in 1,700 public hospitals, 3,000 private hospitals and clinics, and 6,000 cosmetic specialty stores [14]. Group 4: Industry Context - The recombinant collagen and medical beauty sectors are characterized by high profit margins, with Juzi Biotechnology boasting a gross margin of 82% [16]. - The industry has seen significant interest and investment, with Juzi Biotechnology's IPO in 2022 raising 584 million HKD and subsequent financing rounds in 2024 raising over 16 billion HKD [16].

Core Viewpoint - The article discusses the recent controversy surrounding Juzi Biotechnology, particularly allegations of false advertising regarding its collagen products, leading to a significant drop in its stock price and market value [1][3][6]. Group 1: Allegations and Company Response - A beauty influencer, "Big Mouth Doctor," accused Juzi Biotechnology of selling a collagen product with insufficient collagen content, claiming it was only 0.0177%, which is below the required 0.1% for non-trace ingredients [3][6]. - Juzi Biotechnology's brand, Kefu Mei, issued a statement denying these allegations, asserting that their tests showed collagen content exceeding 0.1% and that they would conduct further third-party tests to verify this [6]. Group 2: Company Background and Market Position - Juzi Biotechnology, led by its actual controller, Fan Daidi, is a leader in the recombinant collagen field in China, with a product range that includes functional skincare, medical dressings, and medical devices [7]. - The company has seen rapid growth, with revenue increasing from 0.9 billion to 5.5 billion from 2019 to 2024, and net profit rising from 0.55 billion to 2.06 billion during the same period [8]. Group 3: Financial Performance and Market Dynamics - In 2024, Kefu Mei generated 4.54 billion, a year-on-year increase of 62.9%, while another brand, Keli Jin, achieved 0.84 billion, up 36.3% [8]. - Juzi Biotechnology's gross margin is reported at 82%, significantly higher than many comparable companies in the industry, which typically range from 70% to 90% [8]. Group 4: Recent Financing Activities - Despite strong financial performance, Juzi Biotechnology has engaged in multiple financing rounds, including an IPO in 2022 that raised 0.584 billion and a recent placement in 2024 that raised 1.641 billion [9].

Core Viewpoint - The controversy surrounding the collagen product "Kefumei" from Giant Biological has escalated due to allegations of ingredient falsification, leading to a crisis of trust among investors and consumers [5][6][10]. Company Summary - Dr. Hao Yu published a report claiming that the collagen content in "Kefumei" is only 0.0177%, significantly below the stated minimum of 0.1%, and that key component glycine was not detected [5][10]. - Giant Biological quickly responded to the allegations, asserting that their products comply with regulatory standards and that they have commissioned multiple third-party testing agencies to verify the collagen content [12][15]. - The company emphasized that their products have passed strict regulatory reviews and that the testing methods used by Dr. Hao Yu are not recognized by industry standards [15][12]. - As of May 25, "Kefumei" has sold over 1 million units, contributing significantly to the company's revenue, with sales projected to reach 27.88 billion yuan and 45.42 billion yuan in 2023 and 2024, respectively [17][19]. Industry Summary - The incident highlights a broader issue within the recombinant collagen industry, where there is currently no unified testing standard, leading to discrepancies in results from different testing methods [22]. - The controversy reflects a struggle between technical standards and commercial interests, with the ultimate resolution depending on consumer trust and regulatory oversight [22]. - The need for transparency in testing and a shift from marketing-driven to technology-driven strategies is critical for the long-term success of companies in the recombinant collagen sector [22].